Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Improved disease markers suggest dual response in a patient with metastatic castration resistant prostate cancer and chronic lymphocytic leukemia following active cellular immunotherapy

Fig. 2

Pattern of IgG and IgM antibody titers following APC8015 treatment. Initial APC8015-2 (investigational form of sipuleucel-T produced using 2 μg/mL of PA2024) in December 2010 and with commercial sipuleucel-T (10 μg/mL PA2024) in December 2012. Rechallenge with commercial sipuleucel-T led to more robust IgG and IgM antibody titers. PAP prostatic acid phosphatase, PA2024 fusion protein comprised of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us